AUPH
Aurinia Pharmaceuticals Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 100 | +2 | 47.31M | $802.51M | +6 | −5 |
| Q1 2026 | 102 | +4 | 44.87M | $664.75M | +6 | −2 |
| Q4 2025 | 99 | 0 | 44.16M | $700.36M | — | — |
| Q3 2025 | 19 | 0 | 27.17M | $300.26M | — | — |
| Q2 2025 | 16 | +1 | 17.49M | $148.13M | +1 | — |
| Q1 2025 | 12 | 0 | 8.38M | $67.38M | +1 | −1 |
| Q4 2024 | 12 | +2 | 8.32M | $74.71M | +3 | −1 |
| Q3 2024 | 9 | 0 | 3.64M | $26.69M | — | — |
| Q2 2024 | 9 | — | 3.40M | $19.43M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.76M | — | $10.07M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Citadel Advisors ✦ | 937.79K | — | $5.35M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | AQR Capital Management ✦ | 202.24K | — | $1.15M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 4 | Renaissance Technologies ✦ | 201.50K | — | $1.15M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Norges Bank ✦ (passive) | 114.05K | — | $651,197 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 85.89K | — | $490,455 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | T. Rowe Price ✦ | 45.71K | — | $261,000 | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Gotham Asset Management ✦ | 40.29K | — | $230,067 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Millennium Management ✦ | 11.77K | — | $67,207 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 256 holders, 73.58M shares, $1.06B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 11.94K sh · $190,427
Officer · 20.98K sh · $355,946
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
3.7% of class · View original SEC filing ↗
10.0% of class · View original SEC filing ↗